[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053348":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":22,"locations":28,"responsibleParty":44,"collaborators":48,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":21,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":21,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":73,"overallStatus":30,"whyStopped":21,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Kisspeptin administration","EXPERIMENTAL","Single bolus of kisspeptin",[13],"Drug: Kisspeptin 112-121",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Kisspeptin 112-121",[9],[20],"Metastin 45-54",null,[23],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"Study Coordinator","CONTACT","617-643-2308","MGHKisspeptinResearch@partners.org",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-71.05977,42.35843,{"lat":40,"lon":39},[43],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"SPONSOR_INVESTIGATOR","Stephanie B. Seminara, MD","Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine",[49],{"name":50,"class":51},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIH","100053348","phase-1-kisspeptin-to-quantify-gnrh-neuronal-function-in-health-and-disease-100053348",false,"NCT07224490","Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease","Inclusion Criteria\n\n* Female (ages 18-45 years) or Male (ages 18-60 years)\n* No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration\n* For women, negative serum hCG pregnancy test\n* For cases, diagnosis of post-covid-19 syndrome\n* For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome\n\nExclusion Criteria\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol or the interpretation of results\n* Active use of illicit drugs (not including marijuana)\n* For women,\n* Pregnant\n* Trying to become pregnant during protocol participation\n* Breast feeding\n* Surgical or natural menopause","ALL","18 Years","60 Years",{"count":62,"type":63},40,"ESTIMATED","INTERVENTIONAL",[66],"PHASE1","The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.",[69,70,71,72],"Reproductive Disorder","Neurodegeneration","SARS-CoV 2","Long COVID",[74,70,71,75,72],"Reproductive disorder","Kisspeptin","2026-07-09",{"date":78,"type":79},"2026-07-13","ACTUAL",{"date":81,"type":79},"2026-03-10",{"date":83,"type":63},"2030-05",{"name":46,"class":6},1]